Rhumbline Advisers Buys 10,608 Shares of Trevi Therapeutics, Inc. $TRVI

Rhumbline Advisers raised its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 13.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 90,482 shares of the company’s stock after purchasing an additional 10,608 shares during the period. Rhumbline Advisers owned 0.09% of Trevi Therapeutics worth $569,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its stake in Trevi Therapeutics by 10.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,925 shares of the company’s stock valued at $113,000 after purchasing an additional 1,627 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Trevi Therapeutics by 2.1% during the first quarter. American Century Companies Inc. now owns 79,796 shares of the company’s stock valued at $502,000 after buying an additional 1,653 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Trevi Therapeutics by 20.4% during the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock valued at $174,000 after buying an additional 4,688 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Trevi Therapeutics by 15.1% during the first quarter. MetLife Investment Management LLC now owns 44,656 shares of the company’s stock valued at $281,000 after buying an additional 5,871 shares during the last quarter. Finally, Corebridge Financial Inc. grew its holdings in shares of Trevi Therapeutics by 21.3% during the first quarter. Corebridge Financial Inc. now owns 36,503 shares of the company’s stock valued at $230,000 after buying an additional 6,412 shares during the last quarter. 95.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TRVI. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. Raymond James Financial reduced their price objective on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Needham & Company LLC reduced their price objective on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, August 8th. HC Wainwright began coverage on shares of Trevi Therapeutics in a report on Wednesday, May 28th. They set a “buy” rating and a $21.00 price objective for the company. Finally, Wall Street Zen cut shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, Trevi Therapeutics has a consensus rating of “Buy” and an average price target of $21.75.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $8.55 on Tuesday. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -20.36 and a beta of 0.71. Trevi Therapeutics, Inc. has a 52 week low of $2.36 and a 52 week high of $9.92. The firm’s 50-day simple moving average is $7.59 and its two-hundred day simple moving average is $6.71.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.